Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort Margaret Rosenfeld, Julia Emerson, Sharon McNamara,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

The prevalence of “risky behaviour” in adults with cystic fibrosis

Treatment compliance in children and adults with Cystic Fibrosis

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

Michael Anstead, Sonya L. Heltshe, Umer Khan, Joseph T

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Early attained weight and length predict growth faltering better than velocity measures in infants with CF Sonya L. Heltshe, Drucy S. Borowitz, Daniel.

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

The ease of breathing test tracks clinical changes in cystic fibrosis

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited Abaigeal D. Jackson, Leslie Daly,

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Lucas R. Hoffman, Hemantha D. Kulasekara, Julia Emerson, Laura S

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Claire Keating, Armeen D

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

A.H. Gifford Journal of Cystic Fibrosis

Initial evaluation of the Parent Cystic Fibrosis Questionnaire—Revised (CFQ-R) in infants and young children Adrianne N. Alpern, Lyndia C. Brumback,

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Cystic fibrosis transmembrane conductance regulator gene variants are associated with autoimmune pancreatitis and slow response to steroid treatment

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Chee Y. Ooi, Peter R. Durie Journal of Cystic Fibrosis

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Higher risk of hospitalization among females with cystic fibrosis

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

V. Terlizzi, A. Tosco, R. Tomaiuolo, A. Sepe, N. Amato, A. Casale, C

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Absence of a gender gap in survival

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort Margaret Rosenfeld, Julia Emerson, Sharon McNamara, Valeria Thompson, Bonnie W. Ramsey, Wayne Morgan, Ronald L. Gibson Journal of Cystic Fibrosis Volume 11, Issue 5, Pages 446-453 (September 2012) DOI: 10.1016/j.jcf.2012.04.003 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Kaplan–Meier survival curves for age at initial acquisition of Pseudomonas aeruginosa. a: EPIC observational cohort vs CFNPR replication cohort. b: Among EPIC Observational study participants, by CFTR functional class. Journal of Cystic Fibrosis 2012 11, 446-453DOI: (10.1016/j.jcf.2012.04.003) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions